Post-Hoc Live: What's making biotech IPOs work again? on July 14, 2026 Aktis Bassas da India biotech IPOs clinical proof-of-concept easing Eikon Hemab Therapeutics IPO IPO Kailera Therapeutics IPO Kardigan IPO M&A surge Neoplasms Post-Hoc Live TEAD2 gene Window (physical object) +
Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026 on January 13, 2026 Aktis AKTS Biotech IPOs bounce capital markets CD276 gene Eli Lilly backing IPO NECTIN4 gene Neoplasms Radiopharmaceuticals Window (physical object) +
Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026 on January 12, 2026 Aktis AKTS Biotech IPOs bounce capital markets CD276 gene Eli Lilly backing IPO NECTIN4 gene Neoplasms Radiopharmaceuticals Window (physical object) +
Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026 on January 12, 2026 Aktis AKTS Biotech IPOs bounce capital markets CD276 gene Eli Lilly backing IPO NECTIN4 gene Neoplasms Radiopharmaceuticals Window (physical object) +
Aktis Oncology’s 25% IPO jump lifts optimism for a biotech IPO rebound in 2026 on January 09, 2026 Aktis AKTS Biotech IPOs bounce capital markets CD276 gene Eli Lilly backing IPO NECTIN4 gene Neoplasms Radiopharmaceuticals Window (physical object) +
VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026 on January 08, 2026 2026 AI-driven Attitude Funding Investments IPO M&A activity MassBio rates venture capital Vital capacity Window (physical object) +